DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

This latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 51, 54, 1, 2, 58, 12 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 7, 10 and 6 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Chronic Lymphocytic Leukemia (CLL) - Overview Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development Chronic Lymphocytic Leukemia (CLL) - Drug Profiles Chronic Lymphocytic Leukemia (CLL) - Dormant Projects Chronic Lymphocytic Leukemia (CLL) - Discontinued Products Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones Appendix

For more information about this report visit https://www.researchandmarkets.com/research/qmc7hf/chronic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006709/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Leukemia Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 04:40 PM/DISC: 06/05/2018 04:40 PM

http://www.businesswire.com/news/home/20180605006709/en